FDA Extended the Only U.S.-Licensed Coral Snake Antivenin Lot
FDA extended one North American coral snake antivenin lot through December 31, 2026, highlighting an emergency-medicine supply chain held together by stability data.
Topics
- Published
- Jul 5, 2026, 9:25 AM EDT
- Updated
- Jul 5, 2026, 9:25 AM EDT
- Reviewed
- Jul 5, 2026
- Status
- Confirmed
- Original source
- FDA
- VV source card
- Source graph record
- Verification
- Primary / regulatory source
- Confidence
- very high
- Urgency
- high
Rapid orientation
The 5-second read
- What happened
- This is an expiration-date extension for a specific lot based on FDA-reviewed data, not a new antivenin approval or a general statement that expired drugs are safe.
- Why it matters
- Emergency medicine sometimes depends on fragile biologic supply chains.
- Status
- Confirmed
- Overclaim risk
- Medium
- Primary source
- FDA (Official)
- Next thing to watch
- Supply replacement plans, additional extensions, new licensed alternatives, hospital stocking, and poison-center or emergency-department guidance.
Signal context
Known so far
- Product
- North American Coral Snake Antivenin
- Lot
- CL6814
- Extension
- Through December 31, 2026
- Reason
- FDA-reviewed stability and potency data
- Access boundary
- FDA states no alternative licensed U.S. product for coral snake envenomation
VV Brief Matrix v1.0
VV Brief Signal Score
A derived editorial signal score for how timely, source-backed, important, and bounded this brief is. It helps explain why we covered the story now. It is not a medical evidence score or treatment recommendation.
86/100
Breakout Brief
- Source proximity
- 92/100, weight 18%
- Verification strength
- 90/100, weight 20%
- News cycle urgency
- 88/100, weight 14%
- Human/share signal
- 95/100, weight 12%
- Clinical/scientific importance
- 90/100, weight 16%
- Follow-up value
- 88/100, weight 12%
- Confidence
- 94/100, weight 8%
This brief scores high because human/share signal, confidence, source proximity, but an overclaim penalty of 5 keeps the framing bounded.
Claim Check
ConfirmedFDA extended the expiration date for North American Coral Snake Antivenin Lot CL6814 from June 30, 2026 to December 31, 2026 after reviewing stability and potency data.
Safe framing
This is an expiration-date extension for a specific lot based on FDA-reviewed data, not a new antivenin approval or a general statement that expired drugs are safe.
What happened
FDA extended the use date for North American Coral Snake Antivenin Lot CL6814 through December 31, 2026.
The agency says the extension is based on stability and potency data and matters because there is no alternative U.S.-licensed product for coral snake envenomation.
This is a supply-chain story, not a new treatment breakthrough. A critical emergency biologic is being kept available through lot-specific regulatory extension.
The public takeaway should be simple: snakebite remains an emergency. This brief should not become DIY treatment advice.
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No selling your information. Unsubscribe anytime.
By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.
Why it matters
- Emergency medicine sometimes depends on fragile biologic supply chains.
- Antivenin access can be regional, time-sensitive, and hard to replace.
- The story makes drug-shortage infrastructure visible through a vivid patient-risk scenario.
What not to overclaim
- Do not call this a new antivenin approval.
- Do not imply supply is abundant.
- Do not imply expired products are generally safe to use without FDA extension.
- Do not omit that this applies to Lot CL6814 only.
- Do not give snakebite treatment instructions beyond seeking emergency medical care immediately.
Signal context
Context
- Primary topic
- Emergency Biologics Access
- Source date
- Jul 1, 2026
- Source stack
- 3 sources
- Current status
- Confirmed
VV caution: This should be framed as biologics supply and emergency access, not snakebite advice.
Evidence trail
Source stack
- PrimaryOfficialJul 1, 2026FDA: North American coral snake antivenin expiration-date extension
- Additional contextOfficialJul 1, 2026Pfizer: North American coral snake antivenin customer letter
- RegulatoryRegulatoryJan 1, 2026DailyMed: North American coral snake antivenin label
Research map
View associated studies
Research records connected to this brief through canonical sources, topic tags, or timeline events.
CDC: Giardia Clinical Care
CDC: Giardia Clinical Care
Clinical guidance, translated into key findings, limitations, and consumer relevance.
Study record->
CDC: Pinworm Infection Clinical Overview
CDC: Pinworm Infection Clinical Overview
Clinical guidance, translated into key findings, limitations, and consumer relevance.
Study record->
Endocrine Society: Cushing Syndrome
Endocrine Society: Cushing Syndrome
Clinical guidance, translated into key findings, limitations, and consumer relevance.
Study record->
Mayo Clinic: Adrenal fatigue, what causes it?
Mayo Clinic: Adrenal fatigue, what causes it?
Clinical guidance, translated into key findings, limitations, and consumer relevance.
Study record->
Unpasteurized Milk: A Continued Public Health Threat
Unpasteurized Milk: A Continued Public Health Threat
Review, translated into key findings, limitations, and consumer relevance.
Study record->
Related briefs
More brief coverage
Human Breakthrough Desk
Help us find and amplify more stories like this.
Some health stories should not vanish after one news cycle. Support the independent desk finding patient wins, medical breakthroughs, and human stories worth moving.
Support the Human Breakthrough Desk